

CURRICULUM VITAE

BIOGRAPHICAL

David Anthony Clump II, MD, PhD

clumpda2@upmc.edu

Business Phone Clinical: 412-623-6720
Business Phone Administration: 412-623-6720
Office Fax: 412-623-4050

Department of Radiation Oncology
UPMC Shadyside Hospital
5230 Centre Avenue
Pittsburgh, PA 15232

EDUCATION and TRAINING

UNDERGRADUATE:

August 1997
to 1998 Carnegie Mellon University
Pittsburgh, PA 15213

January 1999
to 2001 West Virginia University
Morgantown, WV 26506 Bachelor of Science
Biology

GRADUATE:

August 2001
to May 2008 West Virginia University
School of Medicine / Ph. D Program
Morgantown, WV 26506 Doctor of Medicine
Doctor of Philosophy Immunology
& Microbial Pathogenesis

POSTGRADUATE:

July 2008
to June 2009 West Virginia University
School of Medicine
Morgantown, WV 26506 Transitional Residency

July 2009
to June 2013 University of Pittsburgh Medical Center
Department of Radiation Oncology
5230 Centre Avenue
Pittsburgh, PA 15232 Radiation Oncology Residency
Chief Resident (2012 – 2013)

SPECIAL TRAINING:

2010	Principles and Practice of Gamma-Knife Radiosurgery UPMC, Pittsburgh, PA 15213
2012	ASTRO / AANS Stereotactic Radiosurgery Course for Residents Chicago, IL 60611
2012	UPMC SRS/SBRT Training Program UPMC, Pittsburgh, PA 15232

APPOINTMENTS and POSITIONS**ACADEMIC:**

July 2013 to August 2014	Clinical Assistant Professor University of Pittsburgh, School of Medicine, Department of Radiation Oncology
August 2014 to Sept 2016	Visiting Assistant Professor University of Pittsburgh, School of Medicine, Department of Radiation Oncology
July 2014 to current	Assistant Professor Clinical and Translational Sciences University of Pittsburgh Cancer Institute
July 2015 to current	Assistant Professor University of Pittsburgh, Department of Otolaryngology/Head and Neck Surgery
October 2016 to current	Assistant Professor University of Pittsburgh, School of Medicine, Department of Radiation Oncology
July 2016 to current	Department of Radiation Oncology Translational Research Program Leader
July 2019 to current	Shadyside and Presbyterian Department of Radiation Oncology Medical Director

CERTIFICATION and LICENSURE**SPECIALTY CERTIFICATION:**

2003, 2008 & 2009 (respectively)	Diplomat, Board of Medical Examiners (USLME Steps 1, 2, 3)
2014	Diplomat, American College of Radiology (Board Certification)

MEDICAL or OTHER PROFESSIONAL LICENSURE:

Current	Medical Licensure, State of Pennsylvania (MD-447846)
---------	--

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

2009 – present	American Society of Therapeutic Radiation Oncology
2009 – present	American Board of Radiology
2009 – present	American Association of Physicists in Medicine
2013 – present	Radiosurgery Society
2016 – present	American Society of Clinical Oncology

HONORS and AWARDS

U.S. Steel Corporation/Carnegie Mellon University Scholar	1997 – 1998
Pfizer Award for Scholarship and Service	2001
<i>Phi Beta Kappa</i>	2001
Regional Cancer Center Consortium for Translational Care Award	2006
Intercultural Cancer Consortium Edward L. Reed Memorial Scholar	2006
WVU Research Day Presenter	2008
Pennsylvania Radiological Society Annual Meeting, 2 nd Place Poster	2010
International HMGB1 Society Meeting, 2 nd Place Poster	2011
Roentgen Resident Research Award	2012
Roentgen Resident Research Award	2013
UPMC Leo H. Crip MD Excellence in Patient Care Award	2016
UPMC Hillman Cancer Center Junior Scholar Award	2018
UPMC Leo H. Crip MD Excellence in Patient Care Award	2019

PUBLICATIONS

Refereed articles

1. **Clump, D.A.**, Clem R., Qian, Y., Guappone-Koay, A., Berrebi A.S., and D.C. Flynn. Expression levels of the Src activating protein AFAP-110 are developmentally regulated in brain. *J. Neurobiology*. 2003.
2. **Clump, D.A.**, Qazi, I., Sudol, M., and D.C. Flynn. c-Yes response to growth factor activation. *Growth Factors*. 2005.
3. **Clump, D.A.**, and D.C. Flynn. c-Yes Target Assessment. *Current Biological Data*. 2009.
4. **Clump, D.A.**, Yu J.J., Cho Y, Gao R, Jett J, Zot H, Cunnick J.M., Snyder B, Clump A.C., Dodrill M, Gannett P, Coad J.E., Shurina R, Figg W.D., Reed E, and D.C. Flynn. A Polymorphic Variant of AFAP-110 Enhances cSrc Activity. *Transl Oncol*. 2010
5. Bria, C., Wegner R.E., **Clump D.A.**, Vargo J.A., Mintz A.H., Heron D.E., Burton S.A. Fractionated Stereotactic Radiosurgery for the Treatment of Meningiomas. *J Cancer Res Ther*. 2011.

6. Greenberger, J.S., **Clump, D.A.**, Kagan, V., Bayir H., Lazo, J.S., Wipf, P., Li, S., Gao, X., and M.E. Epperly. Strategies for Discovery of Small Molecule Radiation Protectors and Radiation Mitigators. *Frontiers in Radiation Oncology*. 2012
7. Leeman JE, **Clump DA**, Wegner RE, Heron DE, Burton SA, and AH Mintz. Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases. *Radiation Oncology* 2012.
8. Leeman JE, **Clump DA**, Wegner RE, Heron DE, Burton SA, and AH Mintz. Detection and Treatment of Small Brain Metastases Resulting from Renal Cell Carcinoma Predicts Improved Survival after Stereotactic Radiosurgery. *Journal of Radiation Oncology* 2012.
9. Lim CM, **Clump DA**, Heron DE, and R.L. Ferris. Stereotactic Body Radiotherapy (SBRT) for Primary & Recurrent Head and Neck Tumors. Review. *Oral Oncology* 2013.
10. Wang K, Heron DE, **Clump DA**, Flickinger JC, Kubicek GJ, Rwigema JC, Ferris RL, Ohr JP, Quinn AE, Ozhasoglu C, and Branstetter BF. Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: a retrospective analysis of the impact of margins and automated PET-CT segmentation. *Radiother Oncol*. 2013.
11. **Clump DA**, Leeman JE, Wegner RE, Heron DE, Burton SA, and AH Mintz. Stereotactic Radiosurgery for the Treatment and Palliation of Base of Skull Metastases. *J Radiosurg SBRT*. 2013
12. Bakkenist CJ, Crzambel RK, **Clump DA**, Greenberger JS, Beumer JH, Schmitz JC. Radiation therapy induces DNA damage in peripheral blood. *Oncotarget* 2013.
13. Vargo JA, Kubicek GJ, Ferris RL, Duvvuri U, Johnson J, DO JO, **Clump DA**, Burton S, Heron DE. Adjuvant stereotactic body radiotherapy ± cetuximab following salvage surgery in previously-irradiated head-and-neck cancer. *Laryngoscope*. 2013.
14. Leeman JE, Heron DE, **Clump DA**, Flickinger JC, Mintz AH, Burton SA. Extent of peri-lesional edema differentiates radionecrosis from tumor recurrence following stereotactic radiosurgery for brain metastases. *Neuro Oncol*. 2013
15. Horne ZD, **Clump DA**, Vargo JA, Shah S, Beriwal S, Burton SA, Quinn AE, Schuchert MJ, Landreneau RJ, Christie NA, Luketich JD, Heron DE. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy. *Radiat Oncol*. 2014
16. Davis KS, Vargo JA, Ferris RL, Burton SA, Ohr JP, **Clump DA**, Heron DE. Stereotactic body radiotherapy for recurrent oropharyngeal cancer - influence of HPV status and smoking history. *Oral Oncol*. 2014
17. Vargo JA, Ferris RL, **Clump DA**, Heron DE. Stereotactic Body Radiotherapy as Primary Treatment for Patients with Medically Inoperable Head and Neck Cancer. *Frontiers in Radiation Oncology*. 2014
18. Vargo JA, Ferris RL, Ohr J, **Clump DA**, Davis KS, Duvvuri, U, Kim S, Johnston JT, Bauman JE, Gibson MK, Branstetter BF, Heron DE. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. *Int J Radiat Oncol Biol Phys*. 2015.

19. Xu KM, Quan K, **Clump DA**, Ferris RL, Heron DE. Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy. *Front Oncol*. 2015.
20. Holt DE, Gill BS, **Clump DA**, Leeman JE, Burton SA, Amankulor NM, Engh JA, Heron DE. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. *Front Oncol*. 2015.
21. **Clump DA**, Bauman JE, Ferris RL. Cancer of the Oropharynx. *Surg Oncol Clin N Am*. 2015.
22. Gill BS, **Clump DA**, Burton SA, Christie NA, Schuchert MJ and Heron DE. Salvage stereotactic body radiotherapy for locally recurrent non-small cell lung cancer after sublobar resection and I-125 vicyl mesh brachytherapy. *Front Oncol*. 2015.
23. Pennathur A, Luketich JD, Heron DE, Schuchert MJ, Bianco V, **Clump D**, Burton S, Abbas G, Gooding WE, Ozhasogul C, Landreneau RJ, Christie NA. Stereotactic Radiosurgery/Stereotactic Body Radiotherapy for Recurrent Lung Neoplasm: An Analysis of Outcomes in 100 Patients. *Ann Thor Surg* 2015.
24. Quan K, Xu KM, Lalonde R, Horne ZD, Bernard MD, McCoy C, **Clump DA**, Burton SA, Heron DE. Treatment Plan Technique and Quality for Single-Isocenter Stereotactic Ablative Radiotherapy for Multiple Lung Lesions with Volumetric-Modulated Arc Therapy or Intensity-Modulated Radiosurgery. *Front Oncol*. 2015.
25. Davis KS, Lim CM, **Clump DA**, Heron DE, Ohr JP, Kim S, Duvvuri U, Johnson JT, Ferris RL. Tumor Volume as a Predictor of Survival in Human Papillomavirus-Positive Oropharyngeal Cancer. *Head Neck* 2015.
26. Newman WC, Williams L, Duvvuri U, **Clump DA**, Amankular N. Hyalinizing Clear Cell Carcinoma with Biopsy Proven Spinal Metastases: Case Report and Review of the Literature. *World Neurosurg*. 2016.
27. Glaser SM, Mandish SF, Gill BS, Balasubramani GK, **Clump DA**, Beriwal S. Anaplastic thyroid cancer: Prognostic factors, patterns of care, and overall survival. *Head Neck*. 2016.
28. Quan K, Xu KM, Zhang Y, **Clump DA**, Flickinger JC, Lalonde R, Burton SA, Heron DE. Toxicities following Stereotactic Ablative Radiotherapy of Locally-Recurrent and Previously-Irradiated Head and Neck Squamous Cell Carcinoma. *Seminars in Radiation Oncology*. 2016.
29. Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, **Clump DA**, Heron DE, Beriwal S. Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC TNM criteria for positive oropharyngeal carcinomas. *Cancer* 2016.
30. Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, **Clump DA**, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL. Phase II randomized trial of radiation therapy, cetuximab and pemetrexed with or without bevacizumab in patients with locoregionally-advanced head and neck cancer. *Ann Oncol*. 2016.
31. Ling DC, Vargo JA, Ferris RL, Ohr J, **Clump DA**, Yau Wy, Duvvuri D, Kim S, Johnson JT, Bauman JE, Branstetter BF, Heron DE. Risk of Severe Toxicity According to Site of Recurrence in Patients Treated with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. *Int J Radiat Oncol Biol Phys*. 2016.

32. Albergotti WG, Davis KS, Abberbock, S, Bauman JE, Ohr J, **Clump DA**, Heron DE, Duvvuri U, Kim S, Johnson JT, Ferris RL. Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma. *Oral Oncol.* 2016.
33. Prabhu AV, Hansberry DR, Agarwal N, **Clump DA**, Heron DE. Radiation Oncology and Online Patient Education Materials: Deviating from NIH and AMA Recommendations. *Int J Radiat Oncol Biol Phys.* 2016.
34. Ling DC, Chapman BV, Kim J, Choby GW, Kabolizadeh P, **Clump DA**, Ferris RL, Kim S, Beriwal S, Heron DE, Duvvuri U. Oncologic outcomes and patient-reported quality of life in patients with oropharyngeal squamous cell carcinoma treated with definitive transoral robotic surgery versus definitive chemoradiation. *Oral Oncol.* 2016.
35. Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, **Clump DA**, Bauman JE, Ohr JP, Gooding WE, Argiris A. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high risk, resected head and neck cancer. *Ann Oncol.* 2016.
36. Vendetti FP, Leibowitz B, Barnes J, Schamus S, Kiessel BF, Abberbock S, Conrads T, **Clump DA**, Cadogan E, O'Connor MJ, Beumer JH, Bakkenist CJ. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. *Sci Rep.* 2017
37. Holt DE, Bernard ME, Quan K, **Clump DA**, Engh JA, Burton SA, Heron DE. Salvage stereotactic radiosurgery for recurrent glioblastoma multiforme with prior radiation therapy. *J Cancer Res Ther.* 2017.
38. Prabhu AV, Crihalmeanu T, Hansberry DR, Agarwal N, Glaser C. **Clump DA**, Heron DE, Beriwal S. Online Palliative Care and Oncology Patient Education Resources Through Google: Do They Meet National Health Literacy Recommendations?. *Pract Radiat Oncol.* 2017.
39. Gebhardt BJ, Ohr JP, Ferris RL, Duvvuri U, Kim S, Johnson JT, Heron DE, **Clump DA**. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. *Amer J Clin Oncol.* 2017.
40. Kikuchi M, Srivastava RM, **Clump DA**, Diaz-Perez J, Sun L, Zeng D, Anderson CJ, Edwards WB, Ferris RL. Preclinical immunePET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma. *OncolImmunology* 2017.
41. Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL. PD-1 status in CD8+ T cells associates with survival and anti-PD-1 therapeutic outcome in head and neck cancer. *Cancer Research* 2017.
42. Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, **Clump DA**, Heron DE, Johnson JT, Hershberg RM, Ferris RL. Phase 1b Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. *Clin Cancer Res.* 2017.
43. Gebhardt BJ, Vargo JA, Ling D, Jones B, Mohny M, **Clump DA**, Ohr JP, Ferris RL, Heron De. Carotid Dosimetry and the Risk of Carotid Blowout Syndrome After Reirradiation with Head and Neck Stereotactic Body Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2017

44. Ling DC, Bakkenist CJ, Ferris RL, **Clump DA**. Role of Immunotherapy in Head and Neck Cancer. *Semin Radiat Oncol*. 2018.
45. Horne ZD, Richman AH, Dohopolski MJ, **Clump DA**, Burton SA, Heron DE. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers. *Lung Cancer* 2018.
46. Vargo JA, Moiseenko V, Grimm J, Caudell J, **Clump DA**, Yorke E, Xue J, Vinogradskiy Y, Moros EG, Mavroidis P, Jain S, El Naqa I, Marks LB, Heron DE. Head and Neck Tumor Control Probability: Radiation Dose-Volume Effects in Stereotactic Body Radiation Therapy for Locally Recurrent Previously-Irradiated Head and Neck Cancer: Report of the AAPM Working Group. *Int J Radiat Oncol Biol Phys*. 2018.
47. Kim H, Vargo JA, Beriwal S, **Clump DA**, Ohr JP, Ferris RL, Heron DE, Huq MS, Smith KJ. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer. *Head Neck*. 2018.
48. Prabhu AV, Randhawa S, **Clump DA**, Heron DE, Beriwal S. What Do Patients Think About Their Radiation Oncologists? An Assessment of Online Patient Reviews on Healthgrades. *Cureus* 2018.
49. Dohopolski MJ, Horne Z, **Clump DA**, Burton SA, Heron DE. Stereotactic Body Radiation Therapy for Pulmonary Oligometastases Arising from Non-lung Primaries in Patients without Extrapulmonary Disease. *Cureus* 2018.
50. Horne DZ, Dohopolski MJ, **Clump DA**, Burton SA, Heron DE. Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to prior high-dose radiation field. *Pract Radiat Oncol* 2018.
51. Vendetti FP, Karukonda P, **Clump DA**, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. *J Clin Invest*. 2018.
52. Sutera P, **Clump DA**, Kalash R, D'Ambrosio D, Mihai A, Wang H, Petro DP, Burton SA, Heron DE. Initial Results of a Multicenter Phase II Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer. *Int J Radiat Oncol Phys*. 2018.
53. Wangaryattawanich P, Branstetter BF, Hughes M, **Clump DA**, Heron DE, Rath TJ. Negative Predictive Value of NI-RADS Category 2 in the First Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma. *AJNR Am J Neuroradiol*. 2018
54. Bauman JE, Duvvuri U, Thomas S, Gooding WE, **Clump DA**, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. *Cancer*. 2018
55. **Clump DA**, Pickering CR, Skinner HD. Predicting Outcome in Head and Neck Cancer: miRNAs with potentially big effects. *Clin Cancer Res*. 2018
56. Sutera P, Kalash R, **Clump DA**, D'Ambrosio, Mihai A, Burton SA, Heron DE. Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases. *Adv Radiat Oncol*. 2018
57. Theodoraki MN, Yernni S, Gooding WE, Ohr J, **Clump DA**, Bauman JE, Ferris RL, Whiteside TL. Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT. *Oncoimmunology*. 2019

58. Nilsen ML, Lyu L, Belsky MA, Mady LJ, Zandberg DP, **Clump DA 2nd**, Skinner HD, Peddada SD, George S, Johnson JT. Impact of Neck Disability on Health-Related Quality of Life among Head and Neck Cancer Survivors. *Otolaryngol Head Neck Surg*. 2019.
59. Ling DC, Vargo JA, Gebhardt BJ, Grimm RJ, **Clump DA**, Ferris RL, Ohr JP, Heron DE. Dose-response modeling the risk of carotid bleeding events after stereotactic body radiation therapy for previously irradiated head and neck cancer. *J Radiosurg SBRT*. 2019.
60. Molkentine JM, Molkentine DP, Bridges KA, Xie T, Yang L, Sheth A, Heffernan TP, **Clump DA**, Faust AZ, Ferris RL, Myers JN, Frederick MJ, Mason KA, Meyn RE, Pickering CR, Skinner HD. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. *Int J Radiat Biol*. 2020.
61. Thomas J, Wang H, Clump DA, Ferris RL, Duvvuri U, Ohr J, Heron DE. Long-Term Patient-Reported Quality of Life After Stereotactic Body Radiation Therapy for Recurrent, Previously-Irradiated Head and Neck Cancer. *Front Oncol*. 2020.
62. Prabhu AV, Leher EJ, **Clump DA**, Kim T. Federal Political Contribution Characteristics of Radiation Oncologists in the United States from 2003-2018. *Int J Radiat Oncol Biol Phys*. 2020.
63. Dharmarajan H, Anderson JL, Kim S, Sridharan S, Duvvuri U, Ferris RL, Solari MG, **Clump DA**, Skinner HD, Ohr JP, Znadberg DP, Branstetter B, Hughes MA, Traylor KS, Seethala R, Chiosea SI, Nilsen ML, Johnson JT, Kubik MW. Transition to a virtual multidisciplinary tumor board during the COVID-19 pandemic: University of Pittsburgh experience. *Head Neck*. 2020.
64. Nilsen ML, Clump DA, Kubik M, Losego K, Mrozek A, Pawlowicz E, Pickford D, Sridharan S, Traylor K, Wasserman-Wincko T, Young K, Zandberg D, Johnson JT. Prevision of multidisciplinary head and neck cancer survivorship care during the 2019 novel coronavirus pandemic. *Head Neck* 2020.
65. Patel AK, Rodriguez-Lopez JL, Hirsch BE, Burton SA, Flickinger JC, Clump DA. Long term outcomes with linear accelerator stereotactic radiosurgery for treatment of jugulotympanic paragangliomas. *Head Neck* 2020.

Book Chapters

1. Kondziolka, D, Niranjan A, Lunsford LD, **Clump DA**, and Flickinger JC. Radiosurgery and radiotherapy for brain tumors. Editors: A.H. Kaye and E.R. Laws Chapter 15. *Brain Tumors 3rd Edition*. 2011.
2. **Clump, D.A.** and Beriwal S. IMRT for Vulvar Cancer. Editor: AJ Mundt. *Radiation Medicine Rounds*. 2011.
3. **Clump, D.A.**, Bauman J.E., and Ferris R.L. Editor: J.A. Ridge. *Management of Oropharyngeal Squamous Cell Carcinoma*. 2014.
4. Dohopolski M, **Clump DA**. Radiation Therapy for Head and Neck Cancer. Editors: Alper C, Meyers EN, Eibling DE., *Decision Making in Otolaryngology*. 2019.

Abstracts

1. **Clump, D.A.**, J.J. Yu, and D.C. Flynn. AFAP in Ovarian Cancer. 97th Annual Meeting for the American Association for Cancer Research. 2006

2. **Clump, D.A.**, R.E. Wegner, D.E. Heron, G. Abbas, M.J., Schuchert, R.J. Landreneau, J.D. Luketich, and S.A. Burton. Stereotactic Body Radiosurgery is a Safe and Efficacious Treatment Modality following RFA for Medically Inoperable NSCLC. ASTRO 2010.
3. **Clump, D.A.**, D.E. Heron, J Engh, A.H. Mintz, J. Cunnick, and D.C. Flynn. The Src Activating Protein, AFAP1 is Positioned to Promote Invasion in Glioblastoma Multiforme. Society of Neuro-Oncology. 2010
4. **Clump, D.A.**, R Srinivas, R. E. Wegner, D.E. Heron, S.A. Burton, and A.H. Mintz, Definitive Chemoradiotherapy and Salvage Fractionated Radiosurgery Resulting in Extended Survival in an Elderly Female with a GBM. Society of Neuro-Oncology. 2010.
5. **Clump, D.A.** R.E. Wegner, C Bria, A.H. Mintz, D.E. Heron, and S.A. Burton, Fractionated Stereotactic Radiosurgery for the Treatment of Meningiomas. ACRO 2011
6. **Clump, D.A.** R.E. Wegner, Christie N, Heron D.E., and S.A. Burton. Stereotactic Body Radiotherapy (SBRT) for Recurrent and Early-Stage Centrally-Located Non-Small Cell Lung Cancer. ASTRO 2011.
7. Wang K, Heron DE, **Clump DA**, Flickinger JC, Rwigema J-C, Ferris RL, Kubicek GJ, Ohr JP, Quinn AE, Ozhasoglu C, Branstetter BF. What is the right margin for target delineation in Stereotactic Body Radiation Therapy (SBRT) for previously irradiated, recurrent squamous cell carcinoma of the head and neck. Oral Presentation. ACRO 2012.
8. **Clump DA**, Lotze MT. Autophagy and HMGB1 expression in Pancreatic Cancer is Modulated by Ionizing Radiation. ARS 2012.
9. Leeman JA, **Clump DA**, Wegner RA, Burton SA, Mintz AH, and DE Heron. Linear Accelerator Based Stereotactic Radiosurgery for the Treatment of Brainstem Metastases. ASTRO 2012.
10. Leeman JE, **Clump DA**, Flickinger JC, Burton SA, Mintz AH, Heron DE. T1/T2 match and high FLAIR lesion-to-edema ratio identify recurrence of brain metastases treated with stereotactic radiosurgery. Society for Neuro-Oncology. 2012.
11. Z. D. Horne, **D. A. Clump**, S. Shah, J. A. Vargo, S. A. Burton, N. A. Christie, M. J. Schuchert, R. J. Landreneau, J. D. Luketich, D. E. Heron. Pretreatment SUVmax as a marker for progression-free survival in stage 1 NSCLC treated with SBRT. ASTRO Cancer Imaging and Radiation Therapy Symposium. 2013
12. Gill BS, **Clump DA**, Vargo JA, Heron DE, Schuchert MJ, Christie NA, Burton SA. Salvage stereotactic body radiotherapy for local failures after sublobar resection with I-125 vicryl mesh brachytherapy. ACRO 2013.
13. Horn ZD, **Clump DA**, Shah S, Vargo JA, Beriwal SD, Burton SA, Christie NA, Schuchert MJ, Landreneau RJ, Pennathur A, Luketich JD, Heron DE. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: location matters. ACRO 2013.
14. Vargo JA, Leeman JA, **Clump DA**, Schuchert MJ, Christie NA, Heron DE, Quinn A, Burton SA. Stereotactic Body Radiotherapy Salvage for Locally-Recurrent Central Non-Small-Cell Lung Cancers. The SRS/SBRT Scientific Meeting 2013.
15. Kabolizadeh P, Horne Z, Shah S, **Clump DA**, Vargo JA, Heron DE, Quinn A, Burton SA, Abbas G, Schuchert MJ. Salvage Stereotactic Body Radiation Therapy (SBRT) for Medically-Inoperable Patients with NSCLC following RFA. The SRS/SBRT Scientific Meeting 2013.

16. **Clump DA**, Vargo JA, Rwigema JC, Davis K, Ferris R, Heron DE, Quinn A, Burton SA. Stereotactic Body Radiotherapy for Recurrent Oropharyngeal Cancer- Influence of HPV and Smoking History. Oral Presentation. The SRS/SBRT Scientific Meeting 2013.
17. Davis KS, **Clump DA**, Chiosea SI, Ferris RL, Johnson JT, Duvvuri U. Patterns of Cervical Metastases in T1/T2 Squamous Cell Carcinoma of the Tongue Base. The Triological Society. 2013.
18. Vargo JA, Ferris RL, **Clump DA**, Burton SA, Heron DE. Stereotactic Body Radiation Therapy ± Cetuximab as Primary Treatment for Elderly Patients With Medically-Inoperable Head-and-Neck Cancer. ASTRO 2013
19. Duvvuri U, Byrd JK, Davis KS, Ferris RL, Kim S, Heron DE, **Clump DA**, Ohr J, Bauman JE, Johnson JT. Transoral Robotic Surgery and the Cervical Unknown Primary: The Utility of Discovering Occult Primary Lesions. ASTRO 2013.
20. Epperly M, Kalash R, **Clump DA**, Heron DE, Burton SA, Engh J, Mintz AH. Breast Cancer Luminal Status Predicts Survival Following Stereotactic Radiosurgery of Brain Metastasis. ASTRO 2013.
21. Rajagopalan MS, **Clump DA**, Heron DE, Flickinger JC, Kubicek GJ, Petro D, Burton SA. Initial Report of a Prospective Phase 2 Study Including Patient-Reported Quality of Life Data of Stereotactic Body Radiation Therapy (SBRT) for Patients With Oligometastatic Disease. ASTRO 2013.
22. Famoso J Berhane H, Kabolizadeh P, Vargo JA, Davis KS, Johnson JT, Heron DE, **Clump DA**. Relationship of Hard Palate Dose and Patient-Reported Xerostomia in Head-and-Neck Cancer Patients Treated with IMRT. ASTRO Multidisciplinary Head and Neck Meeting. 2014.
23. Binks JT, Christie A, **Clump DA**, Burton SA, Christie N, and Heron DE. Failure Rates of SABR treated lung cancer comparing 60 Gray in 3 fractions versus 48 gray in 4 fractions. Radiosurgery Society 2014.
24. Holt DE, Kabolizadeh P, **Clump DA**, Leeman JE, Burton SA, Amankulor N, Engh J, Heron DE. Tumor bed radiosurgery following resection and prior stereotactic radiosurgery for locally persistent brain metastasis. Radiosurgery Society 2014.
25. Horn ZD, **Clump DA**, Shah S, Vargo JA, Beriwal SD, Burton SA, Christie NA, Schuchert MJ, Landreneau RJ, Pennathur A, Luketich JD, Heron DE. Outcome Disparities between Treatment Platforms in the Therapy of Stage 1A/1B Non-Small Cell Lung Cancer with Stereotactic Radiosurgery. Radiosurgery Society 2014.
26. Davis KS, **Clump DA**, Duvvuri U, Johnson JT, Kim S, Bauman J, Ohr J, Heron DE, Ferris RL. Tumor Volume may Predict Survival in HPV-Positive Oropharyngeal Cancer. IFHNOS and AHNS 2014.
27. Ling D, Davis KS, Maxwell JH, **Clump DA**, Heron DE, Kim S, Johnson JT, Ferris RL, Duvvuri U. Quality of Life Outcomes after Transoral Robotic Surgery (TORS) for Oropharyngeal Cancer. IFHNOS and AHNS 2014.
28. Bauman JE, Gooding WE, **Clump DA**, Kim S, Karlovits BJ, Heron DE, Duvvuri U, Ohr J, Holeva K, Ferris RL. Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-14 monoclonal antibody ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma. ASCO 2014.
29. Ferris RL, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, **Clump DA**, Grandis J, Bauman JE, Gooding WE, Argiris A. Phase II trial of radiotherapy with concurrent cisplatin plus panitumumab for patients with high-risk, resected head and neck cancer. ASCO 2014.

30. Horne ZD, **Clump DA**, Burton SA, Heron DE. An Update of Radiosurgical Outcome Disparities by Tumor Location for Early-Stage Non Small Cell Lung Cancer. ASTRO 2015.
31. Quan K, Xu KM, Horne ZD, **Clump DA**, Lalonde R, Burton SA, Heron DE. Treatment Plan Technique and Quality for Single Isocenter Stereotactic Ablative Radiation Therapy of Multiple Lung Lesions with Volumetric Modulated Arc Therapy or Intensity Modulated Radiosurgery. ASTRO 2015.
32. Gill BS, Olsheski ME, D'Ambrosio DJ, **Clump DA**, Wegner RE, Iyer R, Burton SA, Holeva K, Heron DE. Hypofractionated Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer: A Multi-Institutional Phase 2 Analysis. ASTRO 2015
33. Ling DC, Chapman BV, Kim J, Choby G, Kabolizadeh P, **Clump DA**, Ferris RL, Kim S, Beriwal S, Heron DE, Duvvuri D. Oncologic Outcomes and Patient-Reported Quality of Life in Patients with Oropharyngeal Squamous Cell Carcinoma Treated with Primary Transoral Robotic Surgery versus Definitive Chemoradiation. ASTRO 2015.
34. Holt D, Gill BS, **Clump DA**, Si Young J, Burton SA, Flickinger JC, Engh J, Amankulor NM, Heron DE. Clinical Outcomes of Single Isocenter Volumetric Modulated Arc Radiosurgery for Targeting Multiple Brain Metastases. ASTRO 2015
35. Srivastava RM, **Clump DA**, Ferris RL. Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induced better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV + head and neck cancer model. SITC 2015.
36. Holt D, Gill BS, Flickinger JC, **Clump DA**, Burton SA, Engh JA, Heron DE. Repeat Radiosurgery for Locally-Recurrent Brain Metastases with Extensive Peri-Lesional Edema: Increased Risk of Radiation-Related Toxicity? Society of Neuro Oncology 2015.
37. Holt DE, Bernard ME, Quan K, **Clump DA**, Engh JA, Burton SA, Heron DE. (2015) Outcomes of Salvage Radiosurgery for Recurrent Glioblastoma Multiforme. Society of Neuro Oncology 2015
38. Holt DE, Gill BS, **Clump DA**, Engh JA, Flickinger JC, Burton SA, Amankulor NM, Heron DE. Stereotactic radiosurgery in the initial treatment of small brain metastases: local control and prognostic factors of diffuse distant brain failure. ACRO 2015.
39. Holt DE, Gill BS, **Clump DA**, Burton SA, Flickinger JC, Engh JA, Amankulor NM, Heron DE. (2015) Salvage stereotactic radiosurgery for locally recurrent brain metastases treated previously with stereotactic radiosurgery. ARS 2015.
40. Glaser GM, Mandish SF, Gill BS, Balasubramani G, **Clump DA**, Beriwal S. Anaplastic Thyroid Cancer (ATC): Prognostic Factors, Patterns of Care, and Overall Survival. Multidisciplinary HNC Symposium. 2016.
41. Gill BS, Beriwal S, Duvvuri U, Balasubramani G, Heron DE, **Clump DA**. External Beam Radiation Therapy for pT4-Differentiated Thyroid Carcinomas: A National Cancer Data Base (NCDB) Analysis. Multidisciplinary HNC Symposium. 2016.
42. Gebhardt BJ, Ohr J, Bauman JE, Ferris RL, Duvvuri U, Kim S, Johnston JT, Heron DE, **Clump DA**. Primary Salivary Gland Malignancies Treated with Adjuvant Radiation Therapy With or Without Concurrent Chemotherapy: Prognostic Factors and Treatment Outcomes. Multidisciplinary HNC Symposium. 2016.

43. Gebhardt BJ, Bakkenist CJ, Holeva KD, Gill BS, Ferris RL, **Clump DA**. ATM and Gamma-H2AX as Biomarkers of DNA Damage Response and Associations with Toxicity in Patients Undergoing Definitive Radiotherapy (RT) for Head and Neck Cancers. AHNS 2016.
44. Pai, S, Gill BS, Vargo JA, **Clump DA**, Beriwal S, Marks S. Application of multiagent CT among patients with leg-type primary cutaneous B cell lymphoma. ASCO 2016
45. Ferris RL, Kim S, Trivedi S, Srivastava RM, Concha-Benavente F, Heron DE, **Clump DA**, Duvurri, U, Gooding WE, Johnson JT, Ohr J, Bauman JE. Correlation of anti-tumor adaptive immunity with clinical response in a phase II "Window" trial of neoadjuvant cetuximab in patients with resectable stage III-IV head and neck squamous carcinoma (HNSCC). ASCO 2016.
46. Prabhu AV, Hansberry DR, Agarwal N, **Clump DA**, Heron DE. Health Literacy and Radiation Oncology: A Review of Internet-Based Patient Education Materials. ASTRO 2016
47. Li T, Li F, **Clump DA**, Heron DE, Huq MS. Evaluation of kV Cone Beam Computed Tomography-Based Setup Errors in Stereotactic Body Radiation Therapy for Liver Cancer. ASTRO 2016.
48. Quan K, Xu KM, Zhang Y, **Clump DA**, Lalonde R, Burton SA, Heron DE. Estimation of Toxicities Following Stereotactic Ablative Radiation Therapy Treatment of Locally Recurrent and Previously Irradiated Head and Neck Squamous Cell Carcinoma Based on a Normal Tissue Complication Probability Model. ASTRO 2016.
49. Gebhardt BJ, Glaser SM, Beriwal S, Balasubramani GK, Ferris RL, Heron DE, **Clump DA**. Adjuvant Radiation Therapy (RT) With or Without Chemotherapy in Resected High-Risk Salivary Gland Malignancies (SGM): A National Cancer Data Base (NCDB) Analysis. ASTRO 2016.
50. Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, **Clump DA**, Heron DE, Beriwal S. Validation of Proposed Human Papillomavirus Risk-Adapted Staging According to AJCC/UICC TNM Criteria for Positive Oropharyngeal Carcinomas. ASTRO 2016.
51. Ling DC, Vargo J, Ferris RL, Ohr J, **Clump DA**, Yau WYW, Duvvuri U, Kim S, and others. Risk of Severe Toxicity Based on Site of Recurrence in Patients Treated with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer. ASTRO 2016.
52. Horne ZD, Balasubramani GK, **Clump DA**, Ferris RL, Heron DE, Beriwal S. National Patterns of Care and Outcomes of Oropharyngeal Squamous Cell Carcinomas in Patients over 70 in the United States. International Society of Geriatric Oncology 2016.
53. Horne ZD, Dohopolsky MJ, Gabani P, **Clump DA**, Burton SA, Heron DE. Thoracic reirradiation with SABR for residual/recurrent or new primary non-small cell lung cancers within a previously irradiated field: a single institution experience. ACRO 2017
54. Horne ZD, Richman A, **Clump DA**, Burton SA, Luketich JD, Heron DE. Mediastinal/Hilar Stereotactic Ablative Radiation Therapy for Primary and Oligorecurrent Non-Small Cell Lung Cancer. Multidisciplinary Thoracic Symposium. 2017.
55. Kikuchi M, Srivastava RM, **Clump DA**, Diaz-Perez J, Sun L, Zeng D, Anderson CJ, Edwards WB, Ferris RL. Radiation-induced PD-L1 upregulation can be detected by Zr-89-PD-L1 PET/CT in the tumor microenvironment of murine HPV positive HNSCC model and melanoma model. AACR 2017

56. Hatheway CM, Gebhardt BJ, Vargo JA, Ling DC, Ferris RL, Heron DE, **Clump DA**. Patterns of recurrence following stereotactic body radiation therapy of lymph node recurrences of head and neck squamous cell carcinoma. AHNS 2017
57. Prabhu AV, Crihalmeanu T, Hansberry DR, Agarwal N, **Clump DA**, Heron DE, Beriwal S. Online Palliative Care Patient Education Resources: Do They Meet National Health Literacy Recommendations. ARS 2017.
58. Prabhu AV, Randhawa S, **Clump DA**, Heron DE, Beriwal S. What Do Patients Think About Their Radiation Oncologists: An Assessment of Online Patient Reviews on Healthgrades. ARS 2018
59. U.K. Iheagwara, Holeva K, Bakkenist CJ, Shogan J, Engh J, Amankulor N, **Clump DA**. Immuno-Profile of a Phase II Clinical Trial Utilizing Preoperative Stereotactic Radiosurgery Followed by Surgery in Cancer Patients with Metastatic Lesions in the Brain. ASTRO 2018
60. Sutera P, **Clump DA**, Kalash R, D'Ambrosio D, Mihai AM, Wang H, Petro D, Burton SA, et al. Patient Reported-Quality of Life in Oligometastatic Cancer Treated with SBRT: Interim Report of a Phase II Multicenter Clinical Trial. ASTRO 2018
61. Vargo JA, Grimm J, Mavroidis P, Moiseenko V, Jain S, Caudell JJ, **Clump DA**, Das SK, et al. Radiation Dose-Volume Tolerance for Hypofractionated Head and Neck Retreatments: A Report from the HyTEC Normal Tissue Complication Probability Working Group for Carotid Blowout Syndrome. ASTRO 2018
62. Wangaryattawanich P, Branstetter BF, Hughes M, **Clump DA**, Heron DE, Rath TJ. Negative Predictive Value of NI-RADS Category 2 First Post-treatment FDG PET/CT in Head and Neck Squamous Cell Carcinoma. American Society of Neuroradiology 56th Annual Meeting, Vancouver, British Columbia, Canada. 2018
63. Taylor J, Shuai Y, Robertson L, Normolle DP, Ferris RL, Bear T, Nilsen ML, Johnson JT, Kubik M, Sridharan S, Duvvuri U, Wang E, Skinner HD, **Clump DA**, Ohr J, Snyderman C, Chiosea SI, Gish-Johnson R, Kim S, Zandberg DP. The effect of locality of residence and socioeconomic status on mortality in patients with squamous cell carcinoma of the head and neck: 20-year experience at the UPMC Hillman Cancer Center. ASCO 2019.
64. Gillison ML, Ferris RL, Harris J, Colevas DA, Mell LK, Kong C, Jordan RC, Moore K, Truong MT, Kirsch C., **Clump DA**, Ohr J, He K, Blakaj D, Deeken JF, Machtay M, Curran WJ, Le QT. Safety and disease control achieved with the addition of nivolumab to chemoradiotherapy for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. ASCO 2019.
65. Bauman JE, Harris J, Uppaluri R, Yao M, Ferris RL, Chen J, Jordan RC, Joshi NP, Jujjuvapura S, Blakaj D, Razaq M, Sheqwara J, Mell LK, Sen N, **Clump DA**, Garg M, Yilmaz E, Le QT. NRG-HN003: Phase 1 and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy and MK-3475 in high risk head and neck squamous cell carcinoma. ASCO 2019.
66. Mady LJ, Taylor J, Baddour K, Iheagwara UK, Zhai S, Ohr JP, Holeva KD, Quinn AE, **Clump DA**. A Phase II Prospective Trial of Photobiomodulation in Limiting Oral Mucositis in the Treatment of Locally Advanced Head and Neck Cancer Patients. Multidisciplinary Head and Neck Cancer Symposium. Scottsdale, AZ 2020.
67. Zandberg DP, Velez MA, Menk AV, Liu A, Skinner HD, Duvvuri U, Ohr J, Chiosea SI, Nilsen ML, **Clump DA**, Ferris RL, Delgoffe G. The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients. ASCO 2020

68. Reck M, Mileham K, Clump D, Decoster A, Estival E, Felip E, Fried P, Paz-Ares L, Sebastian M, Vinolas Segarra N, Surmont V, Wagner A, Marengoni Galdy S, Smit E. A phase 1/2 trial of radium-223 (Ra-223) in combination with pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC). ESMO 2020.
69. Sherman EJ, Harris J, Bible KC, Xia P, Ghossein RA, Chung CH, Riaz N, Gunn B, Foote RL, Yom S, Wong SJ, Koyfman S, Dzeda MF, Clump DA, Khan S, Chakravarti A, Redmond K, Torres-Saavedra P, Le QT, Lee NY. Randomized Phase II Study of Radiation Therapy and Paclitaxel with Pazopanib or Placebo: NRG-RTOG 0912. ESMO 2020.
-

PROFESSIONAL ACTIVITIES

Teaching:

2004	West Virginia University Teaching Assistant Medical Microbiology/Immunology
2005	West Virginia University Cancer Biology Lecturer: Principles of Radiobiology: PhD candidates
2011, 2020	UPCI Summer Research Academy High School Student Lecturer and Student Mentor
2013	UPCI Summer Research Academy High School Student Lecturer and Student Mentor
2015-17	UPMC SRS/SBRT Training Program Lecturer
2016-17	University of Pittsburgh Medical School Neoplasia Course
2018	Howard Hughes Research Fellowship Co-Mentor: (Pooja Karukonda)
2017-19	University of Pittsburgh DNA Repair Course
2017-20	University of Pittsburgh Head and Neck Surgery Fellowship Lecturer

Research

NIH / CMCR U19 AI068021 (Greenberger) Pilot Project Clump (PI) 09/01/201/-08/31/21
 Signature-Directed, Sequential Delivery of Radiation Mitigators (This is the main title of the CMCR)
 Project aims to characterize the degree and dynamic variability of ATM kinase activity as a biomarker of radiation exposure.

NIH / P50 CA097190 (Ferris) Career Development Award Clump (PI) 07/01/19-06/30/20
Head and Neck SPORE
Work generated as a component of this award led to the identification of phosphorylated ATM as a potential biomarker of DNA response and allowed the prospective collection of this response in relation to radiation induced toxicities.

NIH / CMCR U19 AI068021 (Greenberger) Pilot Project Clump (Co-PI) 09/01/201/-
08/31/21
Signature-Directed, Sequential Delivery of Radiation Mitigators (This is the main title of the CMCR)
This work led to the identification of phosphorylated ATM being elevated 24 hours following the administration of low dose radiotherapy.

AstraZeneca (Bakkenist) Clump (Co-PI) 08/22/16-02/21/19
DNA Damage Response Inhibitors with Radiation and Immunotherapy
AZD0156/ATMi as radiosensitizers: 223Ra (Xofigo) combinations

P50 CA090440 Clump (Co-PI) 09/01/15-08/31/17
Lung SPORE Project 4
Preclinical Assessment of Bioavailable and Orally Active ATR Kinase Inhibitors for the Treatment of Lung Cancer

NIH / 1RO1 CA214018-01 (Anderson) Clump (Co-I) 01/09/17-12/31/21
Image Guided Immunotherapy and targeted radionucleotide therapy of metastatic melanoma

NIH / 1RO1 CA204173-01A1 (Bakkenist) Clump (Co-I) 01/01/17-12/31/21
DNA damage signaling to immune checkpoints

UPMC Cancer Centers (Stanley Marks, MD) Clump (PI) 9/1/14 – 8/31/15
ATM for the Pharmacodynamic Determination of 223Radium Dichloride in Metastatic Bone Disease

UPP Clump (PI) 7/1/17-9/30-18
Modulating Immune Escape with DNA Damage Response Inhibitors

UPP (Bakkenist, Christopher, PhD) Clump (Co-I) 7/1/15-6/30/16
ATR kinase inhibitors for the treatment of lung cancer

Invited Presentations

On Light Sabers and Life Savers: The role of Stereotactic Ablative Radiotherapy. UPCI Cancer Retreat 2013.

Adjuvant Therapies for Parotid Malignancies. Three Rivers Otolaryngology Conference. 2014.

The Evolving Role of Radiotherapy for Brain Metastases: Penn-Ohio Chapter AAPM 2014.

Recurrent HNC treated with SBRT: TCP-based outcome estimates. AAPM. Anaheim, CA. 2015.

Modern Management of Head and Neck Malignancies. Hagerstown, MD. 2015

Dental Management of Patients with Oral Cavity Cancer. Pittsburgh, PA 2013-2017

Oropharyngeal Cancer Management: The Role of Radiation Therapy. AHNS Seattle, WA 2016

Radiation Therapy Advancements: Moderator. Seattle, WA 2016.

The Role of SRS and SBRT in the United States, Rome, Italy 2016.

Radiation therapy in the management of sinonasal malignancies. NASBS. New Orleans, LA 2017

Acute and Late Toxicities of Radiation Therapy. UPMC Survivorship Conference. Pittsburgh, PA 2017

DNA Damage to Immune Checkpoint Signaling: A new era in image guided radiation therapy. AACR-SNMML. San Diego 2018

Radiation and Immunotherapy using DNA Inhibition. New Horizons in Immunotherapy for Head and Neck Cancer. Pittsburgh 2018

Targeting ATR with Radiation. ASTRO San Antonio, Tx 2018

New Light for Oncologic Care. Grand Rounds Northwell Health Great Neck, NY 2018

Skull Base Team Tournament. North American Skull Base Society. Orlando, FL 2019

Recurrent HNSCC Treated with SBRT TCP-Based Outcome Estimates. Radiosurgery Society. San Diego, Ca. 2019.

Research Related Activities

Patent: "Methods for detecting Ovarian Cancer and Anticipating Chemotherapy Response" Application number: 11/707839

University Service

UPMC Department of Radiation Oncology Quality Oversight Committee	2011
UPMC Department of Radiation Oncology Morbidity and Mortality Committee	2011
UPCI Clinical Research Oversight Committee	2013-present
UPMC Department of Radiation Oncology Research Committee	2013-present
UPMC Radiation Safety/HUSC	2014-present
UPMC Department of Radiation Oncology Collaborative Research Committee	2015-present
University of Pittsburgh SoM- Oncology Interest Group- Faculty Advisor	2015-present
UPMC Cancer Centers: Oncology for Emerging Markets (Onc4EM)	2015
UPMC Physics Residency Steering Committee	2016-present
Department of Radiation Oncology Translational Research Program Leader	2016-present
UPMC Hillman Cancer Center Total Quality Council	2019-present
UPMC Presbyterian Shadyside Hillman Cancer Committee	2019-present
Department of Radiation Oncology- Presby/Shadyside Medical Director	2019-present
Department of Radiation Oncology Medical Management Committee	2019-present
Radiation Oncology Co-leader of Head Neck Cancer Program	2019-present
UPMC Hillman- Oncology Physician Executive Management Group (OPEMG)	2019-present
UPMC Hillman Cancer Center Protocol Review Committee (PRC A)	2020-present
UPMC Hillman Cancer Center Physician Telemedicine Lead	2020-present
UPMC Hillman Cancer Compliance Committee	2020-present
UPMC Hillman D3/CTSI Advisory Board	2020-present

Community Activities

Bayer/Xofigo Advisory Board	2013
AAPM Head and Neck SBRT TCP NTCP Working Group	2013-present
World Science Network. Radiation Oncology Advisory Board	2011-present
Frontiers in Radiation Oncology. Review Editorial Board	2013-present
NIH Rare Tumors of the Head and Neck Task Force	2015-present
NRG HNC General Committee	2016-present
Galera Therapeutics Oral Mucositis Advisory Board	2016
Reflexion Consortium Member	2017-present
Physician-Scientist CTEP Radium-223 Project Team	2018
Pittsburgh Lung Cancer Cure Foundation- Board Member	2019-present
American Oncology Institute Tumor Board Member	2019-present